PMID- 32634056
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 36
IP  - 9
DP  - 2020 Sep
TI  - Health-related quality of life and economic burden of chronic lymphocytic 
      leukemia in the era of novel targeted agents.
PG  - 1481-1495
LID - 10.1080/03007995.2020.1784120 [doi]
AB  - OBJECTIVE: To quantify the health-related quality of life (HRQoL) and economic 
      burden of chronic lymphocytic leukemia (CLL). METHODS: Studies were searched 
      through Embase, MEDLINE, PubMed, and Cochrane Library, as well as conference 
      abstracts (1 January 2000-2 June 2019). RESULTS: Overall, 12 and 17 primary 
      studies were included in the HRQoL and economic burden reviews, respectively. 
      Patients with CLL reported impairment in various quality of life domains when 
      compared with healthy controls, including fatigue, anxiety, physical functioning, 
      social functioning, depression, sleep disturbance, and pain interference. Key 
      factors associated with a negative impact on the HRQoL burden of CLL included 
      female gender, increased disease severity, and the initiation of multiple lines 
      of therapy. Economic burden was assessed for patients with CLL based on disease 
      status and the treatment regimen received. The main cost drivers related to CLL 
      were outpatient and hospitalization-related costs, primarily incurred as a result 
      of chemo/chemoimmunotherapy, adverse events (AEs), and disease progression. 
      Treatment with targeted agents, i.e. ibrutinib and venetoclax, was associated 
      with lower medical costs than chemoimmunotherapy, although ibrutinib was 
      associated with some increased AE costs related to cardiac toxicities. Cost 
      studies of targeted agents were limited by short follow-up times that did not 
      capture the full scope of treatment costs. CONCLUSIONS: CLL imposes a significant 
      HRQoL and economic burden. Our systematic review shows that an unmet need 
      persists in CLL for treatments that delay progression while minimizing AEs. 
      Studies suggest targeted therapies may reduce the economic burden of CLL, but 
      longer follow-up data are needed.
FAU - Waweru, Catherine
AU  - Waweru C
AD  - Health Economics, AstraZeneca, Gaithersburg, MD, USA.
FAU - Kaur, Simarjeet
AU  - Kaur S
AD  - Parexel Access Consulting, Parexel International, Mohali, India.
FAU - Sharma, Sheetal
AU  - Sharma S
AD  - Parexel Access Consulting, Parexel International, Mohali, India.
FAU - Mishra, Namita
AU  - Mishra N
AD  - Parexel Access Consulting, Parexel International, Mohali, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200723
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - *Cost of Illness
MH  - Female
MH  - Health Care Costs
MH  - Humans
MH  - Immunotherapy
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*economics/*psychology
MH  - Male
MH  - Molecular Targeted Therapy
MH  - *Quality of Life
OTO - NOTNLM
OT  - Chronic lymphocytic leukemia
OT  - economic burden
OT  - health-related quality of life
OT  - medical economics
OT  - review
EDAT- 2020/07/08 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1080/03007995.2020.1784120 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2020 Sep;36(9):1481-1495. doi: 10.1080/03007995.2020.1784120. 
      Epub 2020 Jul 23.